Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Progenitor Cell Mobilisation

A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF

Bone Marrow Transplantation volume 26, pages 717–722 (2000)Cite this article

Abstract

Stem cell mobilisation can be achieved either by administration of rhG-CSF alone or after high-dose cyclophosphamide (HDCy) plus rhG-CSF. We have compared both mobilisation procedures intra-individually in 43 patients with haematological malignancies. Furthermore, the toxicity data were registered. The CD34+ cell yield was higher after mobilisation with HDCy plus rhG-CSF than after rhG-CSF alone in 21 out of 22 patients who were actually harvested after both procedures. If a patient mobilised insufficiently after rhG-CSF alone, the yield of CD34+ cells after the following HDCy priming was lower compared to patients who mobilised sufficiently after rhG-CSF priming alone. In 12 patients with B cell malignancies a reduced number of B cells such as CD10+, CD19+, CD20+ cells in bone marrow as well as in leukapheresis products was observed after HDCy plus rhG-CSF compared to rhG-CSF alone. Toxicity data revealed HDCy as a relatively toxic priming regimen with all patients hospitalised and 74% experiencing neutropenic fever and administration of intravenous antibiotics. In two patients, seizure-like episodes were observed during cyclophosphamide bolus infusion. In conclusion, HDCy increased the yield of CD34+cell and reduced B cells in leukapheresis products indicating reduced tumour cell load compared with rhG-CSF priming alone. The efficacy of HDCy priming is limited by its profound toxicity and morbidity. Studies evaluating efficacy and safety of lower doses of cyclophosphamide are needed. Bone Marrow Transplantation (2000) 26, 717–722.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Beyer J, Schwella J, Zingsem I et al. Hematopoietic rescue after high dose chemotherapy using autologous peripheral blood progenitor cells or bone marrow: a randomized comparison J Clin Oncol 1995 13: 1328–1335

    CAS  PubMed  Google Scholar 

  2. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients Lancet 1996 347: 353–357

    CAS  PubMed  Google Scholar 

  3. Hartmann O, Le Corroller AG, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized controlled trial Ann Intern Med 1997 126: 600–607

    CAS  PubMed  Google Scholar 

  4. Roos AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collection from breast cancer patients using immunocytochemical and clonogenic assay techniques Blood 1993 82: 2605–2610

    Google Scholar 

  5. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors Blood 1994 83: 636–640

    CAS  PubMed  Google Scholar 

  6. Socinski MA, Elias A, Schnipper L et al. Granulocyte–macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man Lancet 1988 1: 1194–1198

    CAS  PubMed  Google Scholar 

  7. Bensinger WI, Longin K, Appelbaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation Br J Haematol 1994 87: 825–831

    CAS  PubMed  Google Scholar 

  8. To LB, Sheppard KM, Haylock DN et al. Single high doses of cyclophosphamide enable the collection of high numbers of haemopoietic stem cells from the peripheral blood Exp Hematol 1990 18: 442–447

    CAS  PubMed  Google Scholar 

  9. Shepherd KM, Charles P, Sage RE et al. Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignancies Clin Lab Haematol 1991 13: 25–32

    CAS  PubMed  Google Scholar 

  10. Siena S, Bregni M, Brando M et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte macrophage colony-stimulating factor Blood 1989 74: 1905–1914

    CAS  PubMed  Google Scholar 

  11. Knudsen LM, Gaarsdal E, Jensen L et al. Improved priming for mobilization and optimal timing for harvest of peripheral blood stem cells J Hematother 1996 5: 399–406

    CAS  PubMed  Google Scholar 

  12. Johnsen HE, Knudsen LM for the Nordic Stem Cell Laboratory Group (NSCL-G) . Nordic flow cytometry standards for CD34+ cell enumeration in blood and leukapheresis products: report from the second Nordic workshop J Hematother 1996 5: 237–245

    CAS  PubMed  Google Scholar 

  13. Szczepek A, Bergsagel PL, Axelsson L et al. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patients-specific IgH VDJ gene rearrangements Blood 1997 89: 1824–1833

    CAS  PubMed  Google Scholar 

  14. Macintyre EA, Belanger C, Debert C et al. Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH-positive follicular lymphoma patients Blood 1995 86: 4691–4698

    CAS  PubMed  Google Scholar 

  15. Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte–macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer Blood 1992 79: 3036–3044

    CAS  PubMed  Google Scholar 

  16. Möhle R, Pförsich M, Fruehauf S et al. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with the use during steady-state hematopoiesis Bone Marrow Transplant 1994 14: 827–832

    PubMed  Google Scholar 

  17. Cremer FW, Kiel K, Wallmeier M et al. Leukapheresisproducts in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone Exp Hematol 1998 26: 969–975

    CAS  PubMed  Google Scholar 

  18. Knudsen LM, Rasmussen T, Jensen L et al. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment Med Oncol 1999 16: 245–254

    CAS  PubMed  Google Scholar 

  19. Gribben JG, Saporito L, Barber M et al. Bone marrows of non-Hodgkin’s lymphoma patients with bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion Blood 1992 80: 1083–1089

    CAS  PubMed  Google Scholar 

  20. Rasmussen T, Jensen L, Johnsen HE . Clonal cells in patients with multiple myeloma are part of an ongoing differentiation process that may include memory B-cells Acta Oncol 1999 (in press)

  21. Rasmussen T, Jensen L, Honoré L, Johnsen HE . Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myeloma Blood 1999 (in press)

  22. Vora AJ, Toh CH, Peel J, Greaves M . Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration Br J Haematol 1994 86: 180–182

    CAS  PubMed  Google Scholar 

  23. Vescio RA, Hong CH, Cao J et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma Blood 1994 84: 3283–3290

    CAS  PubMed  Google Scholar 

  24. Kimlinger T, Witzig TE . Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma Bone Marrow Transplant 1997 19: 553–556

    CAS  PubMed  Google Scholar 

  25. Rasmussen T, Jensen L, Honoré L, Johnsen HE . Circulating clonal cells in multiple myeloma do not express CD34 mRNA as measured by single-cell and real-time RT-PCR assays Br J Haematol 1999 107: 818–824

    CAS  PubMed  Google Scholar 

  26. Haynes A, Hunter A, McQuaker G et al. Engraftment characteristics of peripheral blood stem cells mobilised with cyclophosphamide and the delayed addition of G-CSF Bone Marrow Transplant 1995 16: 359–363

    CAS  PubMed  Google Scholar 

  27. Rosenfeld CS, Shadduck RK, Zeigler ZR et al. Cyclophosphamide-mobilised peripheral blood stem cells in patients with lymphoid malignancies Bone Marrow Transplant 1995 15: 433–438

    CAS  PubMed  Google Scholar 

  28. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors Bone Marrow Transplant 1992 9: 11–17

    CAS  PubMed  Google Scholar 

  29. Rowlings PA, Bayly JL, Rawling CM et al. A comparison of peripheral blood stem cell mobilisation after chemotherapy with cyclophosphamide as a single agent in doses of 4 g/m2 or 7 g/m2 in patients with advanced cancer Aust NZJ Med 1992 22: 660–664

    CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the Danish Cancer Society, Danish Medical Association (Højmosegård Foundation), Ebba Celinders Foundation and the Foundation of 17-12-1981.

Author information

Authors and Affiliations

  1. Department of Haematology, L Herlev Hospital, University of Copenhagen, Herlev, Denmark

    L Jensen, E Gaarsdal, K Nikolaisen & HE Johnsen

  2. Department of Haematology L, Herlev Hospital, University of Copenhagen, Herlev, DK-2730, Denmark

    LMeldgaard Knudsen

Authors
  1. LMeldgaard Knudsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Jensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E Gaarsdal
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Nikolaisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. HE Johnsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knudsen, L., Jensen, L., Gaarsdal, E. et al. A comparative study of sequential priming and mobilisation of progenitor cells with rhG-CSF alone and high-dose cyclophosphamide plus rhG-CSF. Bone Marrow Transplant 26, 717–722 (2000). https://doi.org/10.1038/sj.bmt.1702609

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702609

Keywords

This article is cited by

Search

Advanced search

Quick links